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Background: Matrix metalloproteinases (MMPs) have long been associated with cancer-cell invasion and metastasis.
Few studies are available that describe this association with bladder cancer either related or unrelated to schistosoma
infection.
Evaluating the urinary levels of MMP3 and MMP9 as diagnostic and prognostic biomarkers in different stages of
schistosomal and non schistosomal bladder cancer was the aim of the present study.
Urine samples were collected from 70 patients with schistosomal and non schistosomal bladder cancer at early and
advanced stages and also from12 healthy volunteers as controls. Urinary levels of MMP-3 and MMP-9 was measured by
ELISA technique. Sensitivity and specificity of both markers were determined.
Results: Urinary levels of both MMP-3 and MMP-9 were significantly elevated in all bladder cancer patients compared
with controls. MMP-3 started to elevate in early stages of schistosomal bladder cancer ( 0.173 ng/ml) and non-schistosomal
bladder cancer patients (0.308 ng/ml) compared to control (0.016 ng/ml) and remained elevated in advanced stages (0.166,
0.235 ng/ml) of both types of bladder cancer patients. In contrast, MMP-9 showed a significant elevation in advanced
stages only of both schistosomal and non schistosomal bladder cancer patients (10.33, 21.22 ng/ml) compared
to control (0.409 ng/ml) and this elevation of both markers was much higher in non schistosomal bladder cancer.
Both Metalloproteinases were specific for the diagnosis of the disease but MMP-3 was more sensitive and this
sensitivity was evident in the early stage (84.85% for MMP3, 27.28% for MMP9).
Conclusions: MMP3 may be the recommended urinary metalloproteinases as early diagnostic biomarker in the
early stages of both types of bladder cancer although both MMP9 and MMP3 can be used in the diagnosis of
advanced stages. Further studies are required on large number of urine samples to confirm these results.
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Bladder cancer is an important public health problem
and is considered the fourth most common malignant
neoplasm in men and the eighth in women where more
than 70,530 new cases were estimated in 2010 account-
ing for more than 14,680 deaths in USA [1]. In Egypt it
is the first site of incidence for males accounting for 17%
of all cancer cases; while in females it accounts for 5%,
ranking first among male cancer with a male/female* Correspondence: felsharkawi@gmail.com
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article, unless otherwise stated.ratio of 3.5:1 [2]. Schistosomiasis has been endemic in
Egypt at least since the time of the ancient Pharaohs, as
indicated by the presence of calcified ova in the Egyptian
mummies [3]. The association of bladder cancer with
schistosomiasis seems to be related to the endemicity of
the parasite, and is considered the main etiologic factor [4].
Matrix metalloproteinases (MMPs) are a large family
of calcium-dependent zinc-containing endopeptidases
that are involved in extracellular matrix (ECM) degrad-
ation. MMPs are capable of degrading extracellular mol-
ecules and a number of bioactive molecules. Twenty
four related genes have been identified in humans, which
can be organized into six groups based on domain
organization and substrate preference. MMPs play atral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Table 1 Demographic data of the bladder cancer cases






Age: Mean 62.77 59.8 61.3 50.5
(years) Range 38-84 44-73 32-84 29-66
Sex: Male 33 19 52 7
Female 3 15 18 5
Disease Stage:
T 1–2
17 16 33 12
T 3-4 19 18 37
Total 36 34 70 12
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ation, angiogenesis, apoptosis and host defenses. It has
been reported that deregulation of MMPs has been im-
plicated in many diseases including arthritis, chronic ul-
cers, encephalomyelitis and cancer [5].
The gold standard for bladder cancer screening is still
urine cytology, as it is non-invasive, safe and inexpen-
sive. Although it is highly specific, the results are not re-
producible and the interpretation is highly dependent on
the skill of the cytologist [6]. This calls for searching
other markers for screening of bladder cancer which
should be specific, sensitive, reproducible, non-invasive
and done at an acceptable cost.
So the aim of the present study was to evaluate the
urinary levels of MMP3 and MMP9 in different stages of
schistosomal and non-schistosomal bladder cancer in
Egyptian patients.
Methods
A prospective analysis was performed on 70 bladder
cancer Egyptian patients who have attended at the cyst-
oscopy unit of the National Cancer Institute, Cairo Uni-
versity, during the period from May 2010 to March 2012
and 12 healthy people with no previous history of any
urological disorders as a control group.
All subjects signed an informed written consent for
participation and the study was approved by the research
ethics committee of the General Organization for Teach-
ing Hospitals and Institutes. Patients demographic data
and medical history were obtained from hospital files.
Pathological grading of cases was based on the World
Health Organization’s classification of urothelialneoplasms
[7]. Staging of bladder cancer was according to the classi-
fication of Union for International Cancer Control (UICC
TNM) [8]. Treatment of the 70 patients included in the
study followed the guidelines adopted at the National
Cancer Institute, Cairo University where all T1 cases were
subjected to transuretheral resection and local BCG, while
radical cystectomy was done for those having T2-3 disease
stage +/−pelvic radiotherapy and/or adjuvant chemother-
apy. T4 cases received neoadjuvant chemotherapy to be
followed by local therapy.
Experimental samples
Patients were classified into:
1. Schistosomal bladder cancer group: 36patients (33
males and 3 females with a mean age of 62.7 and a
range of 38–84 years). Seventeen patients (15 males
and 2 females) presented with early stages of the
disease (T1-T2) and 19 patients (18 males and one
female) had locally advanced disease stages (T3-T4).
2. Non schistosomal bladder cancer group: 34 patients
(19 males and15 females; with a mean age of 59.8and a range of: 44–73 years). Sixteen patients
presented with early stages and 18 patients with
locally advanced stages.
The 12 healthy people that have served as a control
group were matched with sex and age with the bladder
cancer group (Table 1).
Freshly voided urine was collected from all patients and
controls; samples were centrifuged at 1000 rpm and sepa-
rated as urine and urine sediment. All samples were taken
at the time of diagnosis before receiving any treatment.
ELISA
Urinary MMP9 and MMP3 were measured, using a
commercially available ELISA kits provided by R&D Sys-
tems, Inc.614 McKinley, United States of America with
catalog number DMP900 and from Cusabio with cala-
loge number of CSB-E04677h, according to manufac-
turer instructions.
Two microplates of 96 wells each has been pre-coated
with monoclonal antibodies specific for MMP-9 and
MMP3. Standards and urine samples were pipetted into
the wells of each microplate. After washing away un-
bounded substances, an enzyme-polyclonal antibody specific
for each MMp-9 and MMP3 was added to the wells of each
plate. Following washing to remove unbound antibody-
enzyme reagent, a substrate solution was added to the wells
of each plate and a color was developed in proportion to the
amount of MMP-9and MMP3 bounded in the initial step.
The intensity of the color was measured at specific wave
length. Standard curves were plotted using standard concen-
trations on X axis and their optical densities on Y axis.
The concentrations of MMP-9 and MMP3 in urine
samples were determined by comparing the optical
densities (OD) of the samples to the standard curves.
Statistical analysis
The SPSS software system for Windows (version 12.0; SPSS,
Chicago, IL, USA) was utilized for statistical analysis.
A statistical computer program (GraphPadInstat) was
Table 2 Mean urinary levels of MMP9 and MMP3 for
schistosomal and non-schistosomal bladder cancer
patients
A. (MMP9)
Schisto/Stage T 1-T2 stage T 3-T4 stage Total
Non-Schistosomal cases 0.446 21.22**** 10.73
Schistosomal cases 0.544 10.33**** 5.25
Total 0.495 15.78 7.99
B. (MMP3)
Schisto/Stage T 1-T2 stage T 3-T4 stage Total
Non-Schistosomal cases 0.308*** 0.235*** 0.269
Schistosomal cases 0.173*** 0.166*** 0.169
Total 0.241 0.201 0.219
A. Mean value of control group 0.409 ng/ml.
B. Mean value of control group 0.016 ng/ml.
The values were expressed as mean. ****P < 0.0001, ***P <0.001 compared
with control using t test for unpaired data.
El-Sharkawi et al. Journal of Biomedical Science 2014, 21:72 Page 3 of 6
http://www.jbiomedsci.com/content/21/1/72used to test the significance of the difference between
patients groups.
One-way Analysis of Variance (ANOVA) for paramet-
ric data was used to analyze more than two sets of data.
ROC curves generated from ELISA data were used to
measure the diagnostic accuracy of the measured param-
eters. Data was presented as mean value ± SE.
Results
Data was presented as mean value ± SE of the bladder can-
cer patients compared with that of healthy control people.
Urinary matrix metalloproteinases-9 (MMP9)
There was a significant increase of the mean value of
urinary MMP9 level for the whole 70 bladder cancer
cases (7.99 ng/ml) when compared to that of the control
group (0. 409 ng/ml) with a P value of < 0.001. In schis-
tosomal bladder cancer group (36 cases),the level of
MMP9 was elevated significantly to 5.25 ng/ml than that
of controls (P < 0.001).Also this increase in MMP9 was
shown in patients with non-schistosomal bladder cancer
(34 cases, 10.73 ng/ml)compared to control level (P < 0.001).
When comparing the level of MMP9 in schistosomal and
non-schistosomal bladder cancer groups; there was also a
significant elevation of MMP9 in non-schistosomal bladder
cancer group when compared to the schistosomal bladder
cancer group.
There was a variation in the level of MMP9 between
the patients in different stages of bladder cancer com-
pared to control; at stages T1and T2, this variation was
not significant neither in schistosomal bladder cancer
(0.544 ng/ml) nor in non-schistosomal bladder cancer
patients (0.446 ng/ml). In contrast MMP9 was signifi-
cantly highly increased in stages T3 and T4 of both
schistosomal bladder cancer (10.33 ng/ml) and non-
schistosomal bladder cancer patients (21.22 ng/ml) (P <
0.0001) and this increase was much higher in non-
schistosomal bladder cancer than in schistosomal blad-
der cancer patients (Table 2) and (Figure 1).
Urinary matrix metalloproteinases-3(MMP3)
There was a significant difference between the mean level
of urinaryMMP3 of the control group (0.016 ng/ml)
and that of the 70 bladder cancer cases (0.219 ng/ml,
P < 0.001). MMP3 was elevated significantly in both schis-
tosomal bladder cancer (0.169 ng/ml) and non schistosomal
bladder cancer groups (0.269 ng/ml) compared to the con-
trol group (P < 0,001); with more significant increase in non
schistosomal bladder cancer than schistosomal bladder can-
cer patients.
In contrast to MMP9 it was shown that the level of
MMP3 started to elevate significantly ((P <0.001) in pa-
tients with T1and T2 stages (0.241 ng/ml) and remainssignificantly elevated at more advanced T3and T4 stages
(0.201 ng/ml), when compared to controls (0.016 ng/ml).
The significant elevation of MMP3 was much higher
in the early stages of non schistosomal bladder cancer
(0.308 ng/ml, P <0.001) than schistosomal bladder can-
cer (0.173 ng/ml, P <0.001). In more advanced stages of
both types of bladder cancer, MMP3 was similar to
MMP9 in its significant elevation than controls both in
schistosomal bladder cancer (0.166 ng/ml) and non
schistosomal bladder cancer groups (0.235 ng/ml) and
this elevation was higher in non schistosomal bladder
cancer patients (Table 2) and ( Figure 2).Diagnostic accuracy of the investigated biomarkers
ROC curves generated from ELISA were used for meas-
uring the accuracy of both MMP9 and MMP3 at differ-
ent stages of bladder cancer. It was found that both
metalloproteinases were specific for diagnosis of the dis-
ease being 100% for MMP9 and 92.31% for MMP3
(91.67% for early and 100% for late stages). The sensitivity
was variable (Table 3); MMP3 was more sensitive being
86.42% while it was only 64.29% for MMP9. This difference
in sensitivity between the 2 markers was more evident in
the early stages (84.85% for MMP3 compared to 27.28%
for MMP9).Discussion
The majority of the biomarker studies in patients with
bladder cancer have been focused on urine [9]. The as-
sociation between the urinary levels of MMP9 and risks
of bladder cancer as well as stage and grade of disease
was reported in different studies [10], but few studies
are available for MMP3 levels in bladder cancer both

































Figure 1 Mean concentration of urinary MMP9 in schistosomal and non schistosomal bladder cancer. The values were expressed as
mean. ****P <0.0001 compared with control using t test for unpaired data.
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http://www.jbiomedsci.com/content/21/1/72Metalloproteinases are a family of proteolytic enzymes
that degrade all of the main components of the extracellular
matrix and basement membrane [11]. They are associated
with the cell surface and facilitate the invasion of cancer
cells through epithelial cell layers and into nearby stroma
and blood vessels, and generally they are over expressed in
human tumors [12]. Also they are known to participate in
angiogenesis and tumor growth particularly gelatinases
(gelatinase A, MMP2, gelatinase B, and MMP9) [13].
In the current study, urinary MMP9 was not increased

































Figure 2 Mean concentration of urinary MMP3 in schistosomal and n
mean. ***P <0.001 compared with control using t test for unpaired data.related or unrelated to schistosoma infection. Durkan
et al. reported that there was no significant difference in
urinary MMP9 concentrations between patients with
bladder cancer and patients with benign urological disor-
ders; while concentrations of urinary MMP9 were signifi-
cantly higher in urine samples from patients with T3–T4
tumors compared with samples from patients with early
tumors [14]. Also Davies et al. reported that levels of
MMP9 and activated MMP2 were higher in invasive
tumors than in superficial ones [15]. The results of
these two studies are in agreement with our study.0.166***
0.308***
0.235***
on schistosomal bladder cancer. The values were expressed as
Table 3 Sensitivity and specificity of MMP9 and MMP3
for early and advanced stages of bladder cancer patients
A. (MMP9)
Stage/parameter % Sensitivity Specificity
Early stages 27.28 100
Advanced stages 97.3 100
Total 64.29 100
B. (MMP3)
Stage/parameter % Sensitivity Specificity
Early stages 84.85 91.67
Advanced stages 89.19 100
Total 86.42 92.31
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the role of urinary MMP3 in bladder cancer, whether of
schistosomal or non-schistosomal origin.
MMP3 is expressed by fibroblastic cells and by normal
and transformed squamous epithelial cells [16]; where as
MMP9 is strongly expressed in intravascular and tissue-
infiltrating leucocytes [17]. Also MMP3 is one of the
most effective activators for MMP9 [18]. This may ex-
plain the increase in urinary levels of MMP3 rather than
MMP9 in the early stages of both schistosomal and non
schistosomal bladder cancer patients.
In the present study the urinary concentrations of both
MMP3 and MMP9 were much higher in non schistosomal
bladder cancer patients than in schistosomal ones and
these findings are different from those of Fouda et al., who
reported that there was no significant increase in MMP-9
activity in bilharzial related TCC type compared to non
bilharzial one [19]. This controversy may be due to several
issues like the difference in the used methodology between
the two studies since Fouda et al., used zymographic ana-
lysis while ELISA technique was used in the current study,
also Fouda et al., study didn’t identify the stages of the
bladder cancer disease ,it depends on type of cancer
whether TCC or SCC but in our study the selection of the
patients was according to their disease stage whether they
were at early (T1-T2) or advanced (T3-T4) stages which is
considered to be more valuable and more accurate. Fur-
ther more Fouda et al., study included 50 patients and this
difference in number of patients in each study may affect
the obtained results. We agree with Fouda et al., that more
studies are needed in the future, but from our point of
view large number of schistosomal and non schistosomal
patients at different stages of the bladder cancer and with
TCC and SCC must be included.
Conclusions
So in conclusion, measurements of urinary levels of
MMP3 and MMP9 may aid in the diagnosis of both
schistosomal and non schistosomal bladder cancer atdifferent stages. While MMP3 may be used as diagnostic
biomarker in early stages; MMP9 may help as diagnostic
biomarker only in advanced stages. However, further
studies are required on large number of urine samples
to confirm these results especially the role of MMP3 in
the diagnosis of early stages of schistosomal and non
schistosomal bladder cancer.
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